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[18F]THK-5351 was one of first generation tau PET tracers that was designed 
originally to detect tau aggregates in the form of paired helical filaments found in brains of 
patients with Alzheimer’s disease (AD). Previous in vitro autoradiography of [18F]THK-5351 
exhibited the selective binding in a laminar fashion in the cortex of formalin fixed brain 
sections from AD, which corresponded to tau immunohistochemistry1,2). Clinical PET studies 
of [18F]THK-5351 demonstrated that elevated tracer retention in sites susceptible to tau 
deposition in various tauopathies including AD, progressive non-fluent aphasias (PNFA), 
progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS)2-4). However, there 
was high binding of [18F]THK-5351 in the subcortical regions such as the basal ganglia and 
thalamus even in control subjects whose brains are not expected to harbor tau aggregates. In 
addition, the tracer binding in these regions was correlated with age. To understand the 
binding nature of [18F]THK-5351 and identify its targets, we investigated the binding 
property of [18F]THK-5351 using fresh frozen human brain tissues including an autopsy-
confirmed case of AD who underwent [18F]THK-5351 PET scan before death. 
 
Methods 
Experiments were performed under the regulations of the Ethics Committee of the 
Tohoku University Graduate School of Medicine. Postmortem brain tissues from control 
subjects and patients with AD were acquired from Tohoku University Brain Bank and Tissue 
Solutions Ltd (Glasgow, UK). Twelve-micron thick brain slices were generated with a 
cryostat (Microm HM560; Thermo Scientific, Waltham, MA) using a -20°C chamber 
temperature and -15°C object temperature. Sections were transferred to MAS-coated glass 
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slides (Matsunami Glass Ind., Ltd, Osaka, Japan). After drying, the sections were stored 
at -80°C. Brain sections were dried and dipped in PBS for a total of 25 min, and then pre-
incubated in PBS containing 1% bovine serum albumin (BSA). Brain sections were then 
incubated for 30 min at room temperature with 3 nM [3H]THK-5351 (molar activity, 2.96 
TBq/mmol; radiochemical purity, 98.9%, Sekisui Medical Inc., Tokyo, Japan). After 
incubation, sections were washed sequentially with PBS containing 1% bovine serum 
albumin (BSA) for 5 min, followed by PBS for 5 min twice. Dried sections were exposed to 
an imaging plate for tritium (BAS IP TR 2025 E, GE Healthcare, UK) for 3 days. The 
autoradiographic images were obtained from Typhoon FLA-7000 (GE Healthcare). In vitro 
competitive autoradiography was performed in the presence of 3 μM unlabeled ligands or 
inhibitors, which were obtained from Sigma-Aldrich and Tocris Bioscience (Bristol, UK). 
 
Results 
Displaceable binding of [3H]THK-5351 was observed in the basal ganglia of normal 
subjects containing no amyloid plaques and tau tangles (Fig. 1). Competitive autoradiography 
was performed using various ligands whose targets have been reported in human basal 
ganglia. Lazabemide and rasagiline, which are known as reversible and irreversible 
monoamine oxidase-B (MAO-B) inhibitors, respectively, displaced [3H]THK-5351 binding 
completely. However, no remarkable competition was observed with the other tested ligands, 
including a dopamine transporter inhibitor (GBR12935), μ-opioid receptor agonist 
(DAMGO), MAO-A inhibitor (clorygyline), and I2 imidazoline receptor ligand (idazoxan) 
(Fig. 1).  
In vitro autoradiography of [3H]THK-5351 in various regions from an autopsy-
confirmed AD case who underwent [18F]THK-5351 PET scan before death demonstrated 
[3H]THK-5351 binding was substantially reduced in the presence of MAO-B inhibitor, 
Lazabemide, whereas [3H]THK-5351 binding remained detectable , albeit the binding in the 
basal ganglia was completely displaced (Fig. 2).  
 
Discussions 
This study demonstrated that tau PET tracer [18F]THK-5351 bound to MAO-B as well 
as tau aggregates in fresh frozen human brain tissues. A recent human blocking study using 
selective irreversible MAO-B inhibitor, selegiline, confirmed this finding in vivo5). Recent 
imaging-autopsy correlations demonstrated that in vivo [18F]THK-5351 binding was 
correlated with the density of tau aggregates and MAO-B in a patient with AD and PSP6,7). 
128 
 
Previously, we observed selective binding to tau aggregates in paraffin-embedded fixed brain 
sections1,2). However, the fixation of tissues may affect the tracer binding because formalin 
produces cross-linkage of proteins and may result in diminishing the natural binding sites 
such as MAO-B enzymes or yielding the artificial binding sites. In fact, [18F]THK-5351 
binding in the basal ganglia disappeared after fixation (data not shown). These results 




MAO-B is an alternative binding target of [18F]THK-5351. MAO-B is an attractive 
target for in vivo assessment of neuroinflammation such as astrogliosis. Therefore, 
[18F]THK-5351 PET might be useful imaging biomarker for astrocytosis in 
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Figure 1.  In vitro autoradiograms of [3H]THK-5351 in basal ganglia brain sections from a 
normal control subject (83-year-old male) in the absence (no additive) and presence of unlabeled 
THK5351 and various inhibitors/ligands, namely GBR12935 (dopamine transporter inhibitor), 
DAMGO (μ-opioid receptor agonist), clorygyline (MAO-A inhibitor), lazabemide (MAO-B 
inhibitor), rasagiline (MAO-B inhibitor) and idazoxan (imidazoline I2 antagonist). 





Figure 2.  In vitro autoradiography of [3H]THK-5351 in brain sections from an autopsy-confirmed AD 
case (81-y-old male) who underwent [18F]THK-5351 PET scan before death in absence and presence of 
selective reversible MAO-B inhibitor, Lazabemide. Red notes the basal ganglia. 
